Despite being the gold standard for colorectal cancer screening, colonoscopy effectiveness is often compromised by one critical issue: inadequate bowel preparation. In up to 35% of cases, poor prep leads to missed polyps, incomplete exams, and increased repeat procedures.
A new supplement led by GI experts Dr. David Johnson, Dr. Philip Schoenfeld, and Dr. Jack Di Palma revisits updated 2024/2025 ACG®/ASGE® guidelines, advocating for a minimum 90% adequacy rate. The paper outlines the latest metrics, risk impacts of poor prep, and how FDA-approved regimens like SUFLAVE™ and SUTAB® are helping overcome patient hesitancy and improve outcomes.
“Even a ‘fair’ bowel prep increases the risk of missed adenomas and post-colonoscopy cancer,” says Dr. Johnson. The call to action: make prep more tolerable, more personalized, and more precise.
From evidence-backed scoring systems like BBPS to cost-saving strategies, this supplement reframes bowel prep as a quality imperative—not just a prerequisite.